NIH

Dear Research Advocate, It was a privilege to address the terrific crowd at last night’s kick off reception for the American Association for Cancer Research (AACR) Rally for Medical Research. Forceful champions including Senators Durbin (D-IL), Moran (R-KS), Murray (D-WA) and Klobuchar (D-MN) joined NIH Director Francis Collins to thank and encourage the more than 300 advocates who are blanketing both Houses of Congress today. Adding in social media attention, the Rally is likely to reach every member of Congress. During remarks at a Rally breakfast this morning, House “Labor-H” Appropriations Subcommittee Chairman Tom Cole (R-OK-04) revved up the crowd when he said that “the stars are...
Dear Research Advocate: Research!America is proud to serve as a lead sponsor of the American Association for Cancer Research (AACR) Rally for Medical Research, a two-day event in Washington, DC next month. The Rally will unite individuals from across the medical research advocacy community to push for making National Institutes of Health (NIH) funding a higher national priority. Events begin on Wednesday, September 16 with an afternoon advocacy training and an evening congressional reception. On Thursday, after a breakfast featuring remarks by House Labor-HHS-Education Appropriations Subcommittee Chairman Tom Cole (R-OK-04), nearly 200 advocates will participate in Hill meetings. Add your...
Dear Research Advocate, Throughout its 26-year history, Research!America has been fortunate to attract extraordinarily gifted and dedicated national leaders to its Board of Directors. One such leader, the Honorable Louis Stokes, passed away on Tuesday . A powerhouse lawyer, founding member of the Congressional Black Caucus, skilled appropriator, and able chair of the House Ethics Committee, Lou was also a stalwart advocate for medical research and promoted efforts to address health disparities; in so many ways, Lou created a better future for all of us. Our fight for medical progress is, and will continue to be, part of his legacy. Current board member Dr. Herb Pardes wrote a compelling...
Dear Research Advocate, Research!America is on the Hill and in the media continuing to make the case for timely action in Congress to boost medical progress. I appreciated the opportunity to discuss the 21st Century Cures Act and the Senate’s Innovation initiative in a recent issue of Roll Call . The bottom line is this: we need to keep this ball rolling. Congress has a notoriously short attention span - too many issues, not enough time - so advocates should not only be pushing for what they want to see in the Senate bill, they should be pushing to see a Senate bill ASAP. Unless you’ve managed to steer clear of all forms of media in recent days, you probably know that the first official...
This op-ed appeared online on Roll Call July 31, 2015. New technology such as CRISPR-Cas9, a genuine scientific breakthrough, is raising hope for patients with cancer, cystic fibrosis, sickle-cell anemia and other major health threats. The gene editing tool, used in precision medicine, allows changes to be introduced into the DNA of any living cell— potentially enabling repair of disease causing mutations, neutralization of disease carrying insects, and much more. This technology, developed with support from the National Institutes of Health (NIH) and National Science Foundation (NSF), is an example of the realization of the promise of innovative research funded by our federal science...
Strange bedfellows? Not when it comes to research advocacy. On Monday, former House Speaker Newt Gingrich joined Senator Elizabeth Warren (D-MA) and Representative Elijah Cummings (D-MD-07) to press for more R&D in the bioscience arena. Not every topic is one on which Senator Warren and Speaker Gingrich agree , but they found common ground in the benefits that could come from another NIH doubling. The drumbeat for medical research continues apace. The Bipartisan Policy Center (BPC) released what is sure to be an influential report this week, Advancing Medical Innovation for a Healthier America . Focused on the development phase of the discovery, development, delivery continuum, the...
Dear Research Advocate: Congress has postponed further action on patent reform. Concern over provisions in the legislation poured in from a broad coalition within the life sciences community, including universities, patient advocates, and the pharmaceutical and biotech industries. BIO’s Jim Greenwood and PhRMA’s John Castellani penned a compelling op-ed on the topic for The Hill . Now there is more work to be done as policymakers and advocates continue the conversation about reforming our nation’s patent system. Stay tuned. Momentum for a two-year extension of the R&D tax credit is building in the Senate. The Senate Finance Committee, spearheaded by Senator Orrin Hatch (R-UT), voted...
Dear Research Advocate, The “moment” for research that we’ve been experiencing on Capitol Hill is being echoed by Presidential candidates; is this perhaps the start of a wave of conversation on the campaign trail? On Tuesday, the Senate Commerce Committee, which is not the committee of jurisdiction for NIH or FDA, or intellectual property, held a hearing on these very topics. Committee Chairman and Presidential candidate Ted Cruz (R-TX) framed the hearing as an opportunity to explore strategies for speeding cures to patients. The hearing might have devolved into an “FDA regulation is bad” fest, and to be honest there was some of that, but the Senators present, along with the witnesses,...
I am sending my letter early this Thursday to give readers who support the NIH and FDA funding in the 21st Century Cures Act -- most of you, based on the emails and calls I’ve been receiving -- a little more time to take action. The House is slated to vote on the 21st Century Cures Act (HR 6) tomorrow. As part of the process they will first vote on amendments, including one offered by Congressman Dave Brat (R-VA-07) to eliminate the $8.75 billion in mandatory funding for NIH and $550 million for FDA. I can’t stress the importance of stopping this amendment strongly enough: opportunities like this to fund significantly more research do not present themselves often.This is $8.75 billion for...
Dear Research Advocate, This just in--the final version of the 21st Century Cures Act has been filed with the House Rules Committee in anticipation of a House vote next week. And to understate the news: it’s great!! The bill contains mandatory funding of $8.75 billion for the NIH Innovation Fund and $550 million for FDA. Compared to the version that passed the Energy and Commerce Committee, that’s $1.25 billion less for the Innovation Fund over five years. But considering what Reps. Upton (R-MI-06) and DeGette (D-CO-01) were up against in securing this supplemental funding stream, and thinking about what these dollars could mean for medical progress, the end result is a HUGE victory. Click...

Pages

Sidebar Quote

America’s economic destiny lies in innovation, technology, science and research.
The Honorable John E. Porter